News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TopoTarget A/S Grants Exclusive License to Oncology Venture Regarding APO010


11/13/2012 8:08:23 AM

As Topotarget continues to focus its operations on the company’s lead candidate belinostat, the company today announced that it has entered into an exclusive license agreement with Oncology Venture ApS granting Oncology Venture global rights to the further clinical development of APO010.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES